Cervical cancer is a preventable disease. It is also curable if detected early and adequately treated. Yet it is the fourth most common cancer among women globally. Without taking additional action, the annual number of new cases of cervical cancer is expected to increase from 570,000 to 700,000 between 2018 and 2030, while the annual number of deaths is projected to rise from 311,000 to 400,000. “Eliminating any cancer would have once seemed an impossible dream, but we now have the cost-effective, evidence-based tools to make that dream a reality,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. WHO 's global strategy to eliminate cervical cancer proposes: •90% of girls fully vaccinated with the HPV vaccine by 15 years of age •70% of women screened using a high-performance test by age 35 and again by 45 •90% of women identified with cervical disease receive treatment (90% of women with pre-cancer treated and 90% of women with invasive cancer managed)[1].

Sansure's independently developed high-throughput, One-tube fast release technology for HPV PCR test, which can also be paired with mPOCT (iPonatic), enables a breakthrough in molecular diagnostic technology from hourly (5-6h) change to minute (<30min) levels quickly get result . Sansure will actively respond to the implementation of the Health China 2030 strategy and the WHO strategy to accelerate the elimination of cervical cancer, Sansure is committed to making genetic technology available to the general public and will continue to contribute to the accelerated elimination of cervical cancer and improve women's health.